Srikumar B N, Raju T R, Shankaranarayana Rao B S
Department of Neurophysiology, National Institute of Mental Health and Neuro Sciences, Bangalore, India.
Psychopharmacology (Berl). 2007 Aug;193(3):363-74. doi: 10.1007/s00213-007-0801-4. Epub 2007 Apr 28.
Severe, traumatic stress or repeated exposure to stress can result in long-term deleterious effects, including hippocampal cell atrophy and death, which, in turn, result in memory impairments and behavioural abnormalities. The dopaminergic D(2) receptor agonist, bromocriptine, has been shown to modulate learning, and chronic stress is associated with dopaminergic dysfunction.
In the present study, we evaluated the effects of bromocriptine in the presence or absence of restraint stress.
Adult male Wistar rats were subjected to restraint stress for 21 days (6 h/day) followed by bromocriptine treatment, and learning was assessed in the partially baited radial arm maze task. In a separate group of animals, the effects of bromocriptine per se was evaluated. Dopamine levels were estimated by high-performance liquid chromatography with electrochemical detection.
Stressed rats showed impairment in both acquisition and retention of the radial arm maze task, and bromocriptine treatment after stress showed a reversal of stress-induced impairment. Interestingly, in the absence of stress, bromocriptine exhibited dose-dependent differential effects on learning. While rats treated with bromocriptine 5 mg/kg, i.p., demonstrated impairment in learning, the bromocriptine 10 mg/kg and vehicle-treated groups did not differ from normal controls. To understand the neurochemical basis for the effects of bromocriptine, dopamine levels were estimated. The stress-induced decrease in dopamine levels in the hippocampus and frontal cortex were restored by bromocriptine treatment. In contrast, bromocriptine alone (5 mg/kg, i.p.) decreased dopamine levels in the frontal cortex and striatum.
Our study shows that amelioration of stress-induced learning impairment correlates with restoration of dopamine levels by bromocriptine treatment.
严重的创伤性应激或反复暴露于应激状态可导致长期有害影响,包括海马体细胞萎缩和死亡,进而导致记忆障碍和行为异常。多巴胺能D(2)受体激动剂溴隐亭已被证明可调节学习,而慢性应激与多巴胺能功能障碍有关。
在本研究中,我们评估了溴隐亭在有或无束缚应激情况下的作用。
成年雄性Wistar大鼠接受21天的束缚应激(每天6小时),随后进行溴隐亭治疗,并在部分诱饵放射状臂迷宫任务中评估学习情况。在另一组动物中,评估了溴隐亭本身的作用。通过高效液相色谱电化学检测法估计多巴胺水平。
应激大鼠在放射状臂迷宫任务的获取和保持方面均表现出受损,应激后溴隐亭治疗显示应激诱导的损伤得到逆转。有趣的是,在无应激情况下,溴隐亭对学习表现出剂量依赖性的不同影响。腹腔注射5mg/kg溴隐亭治疗的大鼠在学习方面表现出受损,而10mg/kg溴隐亭治疗组和溶剂治疗组与正常对照组无差异。为了解溴隐亭作用的神经化学基础,估计了多巴胺水平。溴隐亭治疗可恢复应激诱导的海马体和额叶皮质多巴胺水平下降。相比之下,单独使用溴隐亭(腹腔注射5mg/kg)可降低额叶皮质和纹状体中的多巴胺水平。
我们的研究表明,溴隐亭治疗改善应激诱导的学习障碍与多巴胺水平的恢复相关。